greenteg AG announces the development of the world`s first fever algorithm for Continuous and Non-Invasive core body temperature tracking on the wrist.

The COVID-19 pandemic has shown how important early detection of fever is to avoid spreading of the disease. But it doesn’t stop with only detecting fever. To guarantee the best possible treatment pathways for patients, monitoring the core body temperature has proven to be one of the most important vital parameters for health professionals. By enabling to track this parameter on the wrist, the acceptance of patients to adhere to continuous monitoring will be further strengthened.

Until two years ago, non-invasive, and continuous tracking of the relevant metric, the core body temperature, has not been possible with wearable devices accurately. greenteg changed that with the chest-worn CORE sensor, and now announces that the R&D department has successfully achieved another breakthrough innovation. Based on data collected on people receiving their second or third COVID-19 vaccination shot, where fever is a common side effect, they developed a new wrist algorithm, which enables detecting fever and continuously tracking its development on the wrist.

Based on the CALERA® solution, greenteg has found a way to compensate the environmental and thermoregulatory influences which are particularly expressed on the wrist. As the wrist is used for thermoregulation, the local temperature behaves opposite to what is observed in the internal organs. It goes down when fever occurs because the body retracts all the heat into its center. Similarly, when the body is recovering from fever, the wrist temperature increases, while the core body temperature sinks to normal levels. These circumstances made the wrist one of the hardest places to measure the core body temperature so far, but with their heat-flux based CALERA® solution and the newly developed algorithm, greenteg now overcomes these problems.

Dr. Lukas Durrer, CTO & Co-founder of greenteg, says: “Developing a fever tracking algorithm on the wrist is like climbing the Mount Everest: both is very hard to do but not impossible. I believe this technology will play a key role in future pandemic monitoring.”

The new wrist algorithm is already in commercialization stage. greenteg could win well-known OEM companies to integrate the Calera® solution into their devices and take advantage of the new fever algorithm for wrist worn devices, one of the first customers is Corsano with the Cardiowatch 287-2.

About greenteg

Founded in 2009 as a spin-off of the Swiss Federal Institute of Technology (ETH), greenteg develops, manufactures, and markets thermal sensors and provides consulting on the thermal integration of its products. Its team consists of 40+ specialists in various engineering disciplines, with all sensors fully developed and manufactured in Zurich, Switzerland.

Today, greenteg supplies original equipment manufacturers (OEMs) and corporate/university labs around the world with its unique products.

Sigknow, a Taiwan-based Digital Healthcare Solution provider, has newly received US Food and Drug Administration (FDA) Class II clearance for its Arrhythmia Diagnostic Solution EZYPRO® in June 2022. This is in addition to the full medical device certifications in the Asian and European markets where EZYPRO® is serving.

EYZPRO®, the No. 1 prolonged ECG monitoring solution in Asia, provides healthcare professionals with patented 14-day ECG patch monitor and diagnosis-ready ECG reports fully curated by CRAT-certified ECG analysts.

“Asia has the most diverse climates, from steamy tropical summers to biting cold winters, and hence presents tough challenges for patches. The hypoallergenic waterproof ECG patch monitor of EZYPRO® can accommodate different wear conditions and provide patients with comfortable ECG monitoring experience for 14 days,” said Sigknow CEO Jiayi Lai. “We work closely with cardiologists and healthcare providers around the globe and support doctors with top-notch ECG reports of detailed arrhythmia information. Our ISO information security certified cloud platform assures doctors and nurses of a hassle-free efficient workflow.”

Behind the clinical-ready EZYPRO® Report which supports cardiologists in their arrhythmia diagnosis is a professional ECG analysis team of US CRAT-certified ECG technicians and nurses. Every ECG report is scrutinized by the team before it is released and delivered to Cardiologists. The proprietary ECG AI analysis software embedded with deep learning algorithm brings accuracy and speed to the EZYPRO® reporting service. “Doctors are often impressed by our report quality, from superb ECG tracing, arrhythmias details, to the user-friendly report presentation. EZYPPRO® is cardiologists’ No. 1 choice for arrhythmia diagnosis.”

With team members and representatives headquartered in Europe, Africa, the Middle East, and the Americas, MediBioSense Ltd. was founded in 2015 and is a multi-award-winning healthcare innovation firm with a focus on wearable solutions that have received medical certification.

In terms of wearable medical technology, MediBioSense is a world leader. By offering comprehensive healthcare solutions and wearable (medically approved) technology, they are revolutionizing the way health is assessed, tracked, and treated. Real-time monitoring of the following clinical physiological data is possible with their wearable technology: Heart Rate, ECG, Respiration Rate, Temperature, Blood Oxygen (Sp02), Posture, and Activity Levels.

You would like to learn more about Medibiosense? Do not miss the chance to meet them at the WT Pavilion at MEDICA 2022 from the 14-17^th of November!

Following its US market launch in 2017, Tempdrop is now available in Europe! Revolutionizing how women around the globe manage their fertility health with an advanced monitor. Tempdrop is both FDA and CE registered as a medical proceptive device and has now initiated regulatory steps to become the first non-hormonal, wearable birth control device.

Tempdrop, a wearable sensor with a smart learning algorithm and fertility app, took on a mission to advance women’s reproductive health throughout every stage. In today’s uncertain times, we at Tempdrop believe every woman should be empowered and equipped with the knowledge to take control of their body. That’s where Tempdrop steps in to provide science-based technology to help you track your cycle and identify your fertile window.

For accurate results, other fertility apps require you to wake at the same hour daily to take your oral temperature. Tempdrop, as a wearable, is accurate and hassle-free. Simply wear the sensor on your upper arm during sleep and sync it with the app whenever it's convenient. Tempdrop is specially tailored to women looking to increase their chances of conceiving or practicing fertility awareness methods. It’s also very helpful for women who are interested in tracking their hormonal health.

Michael Vardi, a biomedical engineer, founded Tempdrop after he and his wife were struggling to conceive their second child. He was determined to find a better way to track the ovulation cycle and pinpoint the optimal time for conception.

Tempdrop has bootstrapped its way since 2017, selling direct-to-consumer, and growing organically by building its vibrant community of followers and promoters. Our motto is ‘know your body,' and with the help of AI & personalized data, we have provided tens of thousands of women across the globe with the tool to do just that.

User reviews:

“Love my Tempdrop! It’s giving me a window into my health and my body that I couldn’t have otherwise and is helping me to be the healthiest I can be. Your cycle is 100% a vital sign of health, don’t ignore it.”

“Huge weight off my mind. I purchased a Tempdrop to be able to better chart my cycles for PCOS and for hopefully conceiving a baby. It seemed to track my temperatures accurately despite multiple night waking, and I was able to use the data to fall pregnant! I'm so glad I found Tempdrop!”

“Very very thankful to have Tempdrop in my life! Would highly recommend this to anyone interested in FAM”

‍

Tempdrop will present at Medica in Dusseldorf this November, a world-leading trade fair for the medical technology industry. Please contact us to arrange a meeting on Zoom or in-person during the event. We’ll be in Hall 12 D33.

Clinical monitoring company Seer Medical has obtained U.S. Food and Drug Administration (FDA) approval of Seer Home™ for the diagnosis of epilepsy via multi-day video-EEG-ECG monitoring. Launched in 2017, today Seer is the leading provider of epilepsy diagnostic monitoring in Australia. With this approval, Seer will be able to offer its home-based long-term monitoring to patients across America, opening up access to life-saving neurological monitoring at scale.

Epilepsy is one of the most common serious neurological conditions, affecting more than 3.4 million Americans and more than 65 million people worldwide. 150,000 people in the United States are diagnosed each year.

Clinical-grade brain and heart monitoring from the comfort of the home

‘Seer Home’ is an ambulatory electroencephalograph (EEG) system designed to be used at the patient’s home for week-long studies. A wearable device - the ‘Seer Sense’ - is worn around the shoulders, with electrodes connected to the skull and chest to record brain (EEG) and heart (ECG) signals. These recordings are wirelessly transmitted to a nearby monitoring hub, which stores the data from the wearable and also records video footage synchronized to the EEG-ECG data.

The recorded video data provides additional context and information to the reviewing physician (such as body movement artifacts) to assist in the diagnosis of the neurological condition. On completion of the study, the technology is returned to Seer, and the collected data is reviewed and annotated by a qualified physician, producing a report for the referring doctor.

A new pathway to diagnosis for Americans

“Seer has demonstrated the effectiveness of ambulant diagnostic monitoring in our home market of Australia. Now with this approval, we are delighted to be able to offer a new pathway to diagnosis for Americans with epilepsy - one that does not require a hospital stay and one that will give doctors the data they need to more accurately diagnose and monitor neurological disorders,” said Dr. Dean Freestone, CEO and Co-Founder, Seer.

The FDA study for Seer Home was completed at the Mayo Clinic in Rochester, and in March 2022, Seer joined the inaugural cohort of the Mayo Clinic Platform Accelerate, to undertake market validation and clinical readiness activities, states a press release.

Dr. Ben Brinkmann, Associate Professor of Neurology at Mayo Clinic highlighted the potential for the system to augment the monitoring capabilities of hospitals and healthcare providers. “Seer's wireless EEG monitoring system and AI-enabled review platform have the potential to help people with epilepsy or other episodic events access the care they need more quickly and with less disruption to their personal lives. This technology may be especially impactful in underserved areas with limited access to neurological health care resources,” said Dr. Brinkmann.

With formal approval from the U.S. Food and Drug Administration, Seer will continue to engage with hospital networks and potential partners across the US, with sights set on addressing the backlog of patients waiting for long-term monitoring.

About Seer Medical

Seer is reimagining how and where people undergo long-term brain and heart monitoring for faster paths to diagnoses and better patient outcomes. Seer’s solutions include an at-home epilepsy monitoring system and wearable medical devices, mobile apps for tracking and forecasting seizures, and cloud technology that translates big data into useful medical insights. Leading health and technology companies around the globe, such as the Mayo Clinic, King’s College London, Fitbit, Epiminder, and Cochlear have partnered with Seer, alongside support from the Australian and American Epilepsy Foundations. Seer is recognized as one of the world’s top private digital health companies by CB Insights, and the company has received numerous product design awards for its wearable device the Seer Sense, including a Gold IF Design Award and Good Design Awards in Social Impact and Medical and Scientific design.

Corsano Health is launching the company’s second-generation wearable device that accurately measures eight vital parameters and makes raw PPG and ACC data available for further analysis by third-party medical algorithm developers.

‍

THE HAGUE, THE NETHERLANDS, October 20, 2022 -- Today, Corsano Health, a leading MedTech company developing, producing, and marketing medical grade continuous health monitoring announced the launch of its CardioWatch 287 at MEDICA 2022, Booth 12D33.

MEDICA is the world‘s largest medical marketplace annually organized in Düsseldorf, taking place this year from 14 – 17 November.

‍

Corsano’s CardioWatch 287 accuracy of a state-of-the-art bracelet has been validated in eight third-party clinical investigations. “The independent validations of Corsano Health’s CardioWatch 287 is important evidence to prove accurate measurement of five vital parameters. Moreover, Corsano offers access to raw PPG and ACC data for further analysis to academic researchers and contract research organizations. Corsano’s non-invasive ergonomic wearables deliver medically validate data with superior patient compliance.” said Drs. Peter Stas, CEO of Corsano Health. "Additionally, patient satisfaction surveys conducted at the closure of the studies cite convenience and ease to use of the CardioWatch 287 devices.”

Due to their non-intrusive and convenient nature, wearable devices like Corsano’s CardioWatch 287 have great potential for high volume accessible long-term monitoring of at-risk patients.

‍

‍

About Corsano Health

Corsano Health, based in The Netherlands with offices in Switzerland, is a leading wearable MedTech company developing, producing and marketing medical smart monitoring devices designed to measure vital parameters 24/7 using wireless, non-invasive, and medical-grade technology. The Corsano brand name is derived from in corpore sano (in a healthy body). Corsano’s CardioWatch 287 is a cardiac arrhythmia screening system that provides a simple and effective method for continuous monitoring of vital parameter measurements (i.e., Heart Rate, RR Intervals, Respiration Rate, SpO2, Sleep, Activity, ECG, BIOZ, Core Body Temperature, Cuffless Blood Pressure). More information at http://www.corsano.com

Pretaa, a US-based behavioral analytics company, that seeks to improve outcomes for the millions of Americans and their families affected by substance abuse, announced a Strategic Partnership with Fitbit Health Solutions, to incorporate Fitbit’s devices and services into their substance abuse recovery offering.

Pretaa analyzes information from wearable devices worn by those recovering from substance abuse disorder and notifies their care providers, friends, and family members when they might need additional support. Fitbit Health Solutions helps partners use Fitbit’s advanced health and wellness platform to drive behavior change and improve outcomes within their populations. The two organizations recognized that together they could use more effectively the technology to help support people recovering from addiction and substance abuse. Pretaa will incorporate Fitbit data into their analytics platform to help providers have a more holistic view of their patients, and members will have access to Fitbit Premium, which provides more personalized and actionable health guidance, according to a press release.

“With this partnership, we’re extending our mission to empower people to live healthier lives,” said Karen Romans, Licensed Clinical Social Worker and Strategic Partner Clinical Lead for Fitbit Health Solutions. “Working with Pretaa, we aim to help providers and caregivers in substance abuse treatment facilities deliver better, more personalized care, armed with actionable information about the health and well-being of their patients.”

“Pretaa’s analytics platform pairs actionable guidance with positive reinforcement to improve treatment outcomes, build resiliency, and reconnect friends and family with their loved ones in recovery,” Michael Madon, the CEO of Pretaa said. “And we are excited to have Fitbit Health Solutions as a technology partner because of their focus on driving behavior change to improve lives, and their ability to deliver a differentiated, personalized, experience focused on health and wellness.”

Read more: Google Seeks FDA Nod For Fitbit’s Passive Heart Rate Monitoring Tech

“Fitbit’s platform, developer support, and sensor suite will allow Pretaa to leverage traditional biometric data (heart rate, SPO2, body temperature) in tandem with robust activity and wellness data (steps and sleep) to provide unique insights derived from our multivariate analyses,” said Dr. John Duselis, Pretaa’s CTO. “This directly supports Pretaa’s hybrid approach, which combines medical domain knowledge and machine learning techniques offering tailored solutions to inform interventions."

About Pretaa

Pretaa is a behavioral analytics company that seeks to improve outcomes for millions of Americans and their families affected by substance abuse. Pretaa does this by analyzing data from wearable devices worn by those recovering from substance abuse disorder and notifying their care providers, friends, and family members when something may have gone wrong so they can get help. And by pairing actionable data and check-ins with positive reinforcement, the platform also fosters trust, communication, and continuity of care with people invested in helping their loved ones and patients throughout the recovery process.

About FHS

Fitbit Health Solutions, now part of Google, works with payers, partners, and employers to empower people to live healthier lives. Fitbit’s personalized health and well-being experience easily integrates into a wide variety of health interventions and well-being programs - including embedded health plan benefits, condition management point solutions, research studies, and corporate wellness programs - and helps to extend and enhance their impact by driving higher participation levels, increasing physical activity, and helping to improve weight loss and diabetes outcomes.

Acurable, an award-winning wearable medical devices company, announced an €11m investment due to its Series A funding round. These funds will be used to accelerate the international expansion of its first product AcuPebble SA100 and drive the company towards its ambition to become the preferred solution for home sleep testing worldwide. The investment was led by Kibo Ventures, along with Mundi Ventures, Kindred Capital, and Comprador Holdings among others.

Acurable's first product AcuPebble SA100 simplifies obstructive sleep apnea (OSA) detection and monitoring by enabling fully automated testing of patients at home for the first time. After successfully launching AcuPebble SA100 in the UK and Spain in 2021, Acurable is now looking to scale up in these two countries and expand into further European markets and North America.

AcuPebble SA100 is the first wearable medical device to obtain a CE mark in Europe for the automated diagnosis of obstructive sleep apnea at home and has received FDA 510(k) clearance in the US. It is also the first device in the world that achieves the accuracy in likelihood ratios required by the US Agency for Healthcare Research and Quality (AHRQ) to consider a diagnostic method equivalent to the gold standard, according to a press release.

This funding follows the recent announcement of a strategic distribution agreement with Nyxoah to provide the AcuPebble SA100 home sleep test to the German market. Acurable's international expansion brings it one step closer to solving the current unmet needs in the diagnosis and monitoring of OSA - a significant issue affecting approximately one billion people globally.

Professor Esther Rodriguez-Villegas, inventor of the AcuPebble technology, co-CEO and founder of Acurable, is a world-renowned scientist and has been awarded some of the highest recognitions in her field. She commented: “The response to AcuPebble SA100 since its launch has been incredible, and we are thrilled to see the product being used to help patients and clinicians in the real world. This funding will help us reach our initial goal of diagnosing one million patients and gives us the opportunity to continue working on new products that will fundamentally improve the lives of millions of people living with severe chronic conditions.”

Read more: BUZUD Launches Smartwatch With Sleep Apnea Detection

Based on contact acoustic sensing, AcuPebble technology is able to automatically extract a wide range of cardio-respiratory disease-related physiological markers. It does this non-invasively and continuously with accuracy comparable to current complex gold-standard methods, which rely heavily on clinical human resources. The technology is ideally positioned to significantly improve the diagnosis and management of some of the most significant chronic respiratory and cardiovascular conditions today. These affect hundreds of millions of people, have significant unmet needs in terms of patient monitoring, and are among the most common causes of death globally. Series A funding will allow Acurable to continue investing in new products for these conditions.

Sonia Fernández, Partner at Kibo Ventures, said: “We are delighted to be joining Acurable’s exciting journey. AcuPebble has the potential to transform the way sleep apnea and other chronic conditions are diagnosed and monitored. It’s much more accurate and easier to use than other devices, and we believe it’s a huge step forward for global healthcare. This is still just the beginning for Acurable and I cannot wait for what comes next.”

About AcuPebble

AcuPebble systems operate on the principle of acoustic sensing, whereby the sounds generated by the body’s physiological functions are sensed with a proprietary non-invasive wearable device. The signals are then transferred wirelessly to a mobile device and to the cloud where algorithms (also proprietary) automatically extract the physiological parameters and indexes used by doctors to diagnose and manage important cardio-respiratory conditions such as obstructive sleep apnoea (OSA).

About Acurable

Acurable is a fast-growing medical devices company with offices in London and Seville. Its award-winning, patented AcuPebble technology enables the automated diagnosis and management of respiratory conditions at home. It builds on the foundation of more than 10 years of research at the Wearable Technologies Lab in the Imperial College London, by Acurable’s founder, Professor Esther Rodriguez-Villegas.

Falls are one of the most significant health and economic issues in Australia and worldwide. In Australia, the treatment of injuries from falls in older people cost the economy $2.3 billion in 2020.

Now, a new algorithm written by researchers from Neuroscience Research Australia (NeuRA) and UNSW Sydney could help promote health in older people and at-risk population reports UNSW. The Watch Walk algorithm measures walking steadiness and speed. By pairing it with a wearable tech device such as a smartwatch, the algorithm can provide real-time feedback on how to improve individual walking stability to reduce falls.

Digital gait biomarkers are quantitative measures of aspects of an individual’s gait, such as posture, cadence, walking speed, and length of stride, that offer insights into the overall health and functional decline and can often predict their likelihood to fall.

Read more: Australian Government Allots US$7 Million to Enhance Healthcare Using Wearables

UNSW Medicine & Health and NeuRA research and co-lead author of the study, Lloyd Chan said it was the first time an algorithm for measuring gait had been widely tested in real-world environments. “We know that the way people walk is a predictor of their health. For example, people who walk more slowly, infrequently, in smaller steps, or for shorter distances are typically more likely to suffer a fall."

“Our goal was to capture this data through looking at how individuals naturally walk in their daily lives and then test this broadly on over 70,000 individuals.”

The new algorithm was created using movement data generated from wrist sensors worn by 101 study participants aged between 19 and 81. The algorithm's validity was later tested in another study involving around 79,000 participants from the UK Biobank database. Participants aged 46 to 77 were instructed to wear wrist devices for a week to record their movements, which were classified into walking, running, stationary, or unspecified arm activity. This study then found the Watch Walk algorithm to precisely measure those movements.

According to the researchers, their two-stage study was the first to widely test an algorithm for measuring gait in real-world environments.

Rite Aid and Google Cloud announced a new, multi-year technology partnership that will help Rite Aid realize its vision of a modern pharmacy. Google Cloud technologies will provide Rite Aid with better insights, increased agility, and improved customer experiences. Modernized applications for personalized digital experiences will enable pharmacists to spend more time directly engaging customers.

As part of the new partnership, Rite Aid will be migrating key applications to Google Cloud's Anthos, a managed platform for application deployment. Applications include Rite Aid's popular vaccine scheduling tool, customer messaging infrastructure, and digital engagement platform. With Anthos, Rite Aid's approximately 2,350 pharmacies will have cloud computing capabilities on-site, providing resilient operations. Strategic business continuity enables the company to continue to provide elevated care during natural disasters through robust patient information, advanced prescription management, and offering recommendations without needing to be connected to centralized, legacy mainframe technology, states a press release.

"The power of pharmacies and the important role pharmacists play in the health of their communities, greatly expanded during COVID. Realizing that potential means making strategic investments in technology that can truly help our customers and maximize the capabilities of our pharmacists," said Justin Mennen, Executive Vice President and Chief Digital and Technology Officer at Rite Aid. "Google Cloud's solutions are uniquely positioned to run at each pharmacy location to allow our store teams to help our customers to achieve whole health for life."

Read more: Google’s Pixel Watch Coming This Fall, Here’s What We Know So Far

In addition to modernizing the technologies powering its pharmacies, Rite Aid has also tapped Google Cloud for digital transformations across other areas of its business, including:

• Complete enterprise data migration: Rite Aid will migrate its enterprise data to Google Cloud using BigQuery. This move will allow the pharmacy to have better insights into its finances, supply chain inventory, and customer information, powering data-driven decisions for its business operations.
• Enhanced search capabilities: Rite Aid has selected Google Cloud's Retail Search solution to provide customers with more precise search results when shopping on Rite Aid's eCommerce site and mobile app. Retail Search will provide Rite Aid customers with an improved search experience that uses Google-quality search models to understand customer intent and takes into account Rite Aid's first-party data (such as promotions, available inventory, and price) for product ranking results.
• Updated pharmacy benefits management application suite: Elixir, Rite Aid's pharmacy benefits and services company, will update its current pharmacy benefits management application suite to a cloud-first experience with artificial intelligence and machine learning-infused business logic capabilities. New Google Cloud data analytics and processing capabilities will help the pharmacy manager to better manage prescription benefits on behalf of health insurers.

"As a healthcare company with a retail footprint, Rite Aid is at the intersection of two quickly evolving industries and making strategic technology investments to meet rising customer expectations," said Carrie Tharp, Vice President of Retail and Consumer Solutions at Google Cloud. "Through these innovations, Rite Aid is defining the modern pharmacy."

About Google Cloud

Google Cloud accelerates every organization's ability to digitally transform its business. They deliver enterprise-grade solutions that leverage Google's cutting-edge technology – allon the cleanest cloud in the industry. Customers in more than 200 countries and territories turn to Google Cloud as their partner to enable growth and solve their most critical business problems.

About Rite Aid Corporation

Rite Aid is a full-service pharmacy that improves health outcomes. Rite Aid is defining the modern pharmacy by meeting customer needs with a wide range of vehicles that offer convenience, including retail and delivery pharmacy, as well as services offered through our wholly owned subsidiaries, Elixir, Bartell Drugs, and Health Dialog. Elixir, Rite Aid's pharmacy benefits and services company, consists of accredited mail and specialty pharmacies, prescription discount programs, and industry-leading adjudication platform to offer superior member experience and cost savings. Health Dialog provides healthcare coaching and disease management services via live online and phone health services. Regional chain Bartell Drugs has supported the health and wellness needs in the Seattle area for more than 130 years. Rite Aid employs more than 6,400 pharmacists and operates approximately 2,350 retail pharmacy locations across 17 states.

As Medtronic continues to await FDA clearance of the latest iteration of its MiniMed insulin pump, the Medtech giant has churned out a steady stream of data supporting the device’s ability to improve outcomes for Type 1 diabetes (IDDM) patients. The latest proof of the MiniMed 780G’s promise arrives in the form of study results published in The Lancet Diabetes & Endocrinology, Medtronic announced Thursday.

The MiniMed 780G system has been cleared in Europe since 2020. Medtronic submitted it to the FDA for U.S. approval in the spring of 2021 but is still awaiting a decision, slowed down by the roadblocks caused by a late 2021 warning letter from the agency that called out quality control issues at the California headquarters of its diabetes business.

In the company's Adapt trial, an insulin pump with an algorithm was compared to the gold standard of care for managing diabetes, which consists of a combination of several daily insulin injections and irregular check-ins using a continuous glucose monitor. The MiniMed device ultimately triumphed in a number of head-to-head comparisons, lowering average blood sugar levels and lengthening the time that individuals stayed within their ideal glycemic ranges, among other things.

The algorithms in the MiniMed 780G gadget enable the wearer's insulin dosages to be automatically adjusted when necessary. Based on wirelessly transmitted data from Medtronic's Guardian glucose monitor, which requires two daily fingerstick calibrations and checks blood sugar levels every five minutes, it makes those decisions, reports FierceBiotech. The MiniMed mobile app that comes with it allows users to monitor those automatic changes. It shows previous trends and real-time glucose readings and may also alert users if their blood sugar levels are rising or falling outside of a predefined range.

The Adapt trial involved 82 people who, before the study, had all been managing their diabetes with a combination of several daily injections and sporadic CGM scans. The patients' average HbA1C levels at the beginning of the trial were above 8%, significantly higher than the advised maximum of 5.7%, despite the fact that their glucose monitors were programmed to take readings roughly nine times each day.

Read more: Tandem Plans to Submit Insulin Pump for FDA Assessment

The experimental group in the research saw an average decline in their blood sugar levels of 1.4% after utilizing the MiniMed 780G system for six months. While none of the individuals in the control group—who continued to rely on the previous standard of care technique to manage their diabetes—reached that level, more than a quarter of those in that group had their HbA1C levels fall below the 7% threshold.

Along with the decrease in blood sugar, by the end of the first six months, those using the MiniMed 780G device were spending an average of 27.6% more time than the control group in their optimum glucose ranges. This equates to an extra 6.6 hours of range time per day, and Medtronic reported that benefits in range time were even more pronounced overnight when the MiniMed system's algorithms were solely in charge of insulin administration.

A lot of individuals use Google to research medical services, including insurance plans like Medicare and Medicaid. Recently, Google announced several health equity-focused updates to its products, including an addition to search that provides information about public insurance programs like Medicare and Medicaid, reports MobiHealthNews.

Announced Thursday in a blog post by Hema Budaraju (Google’s Senior Director of Product, Health, and Search Social Impact) the additions make it easier for patients to seek out doctors near them that fulfill their individual needs, addressing questions like whether a provider accepts Medicare or what languages that provider speaks. "Over the coming weeks, when people search for these programs, they'll see additional information about eligibility requirements and the enrollment process for your state and the federal government. We believe that this can help people enroll more easily into these programs,” Budaraju said during the company's Health Equity Summit.

A 2019 survey found that though 3 in 4 U.S. individuals look for health information online, the majority of those people complain about the difficulty of accessing that information, with older adults complaining more than their younger counterparts.

The tech giant's efforts to provide "timely and authoritative" health information to support individuals in their healthcare journeys are strengthened by the new search options, according to Budaraju.

Read more: Google Shows Off AR Glasses With Translation In Real Time

According to the blog post, individuals on Medicare can now select to filter out all providers that don't accept Medicare while looking for a new doctor on their phones. This enables them to browse only local clinics that guarantee coverage. In order to help people find physicians who speak their preferred language, healthcare practitioners should now list the languages spoken at their offices in their Google profiles. A provider's Google business page can be claimed and updated, and the company aims to regularly verify to make sure the information about nearby clinics is accurate.

"I think particularly in this age, where we're seeing misinformation so prevalent [and] targeted disinformation efforts that are out there to undermine confidence in science and information. It's really critical that we amplify credible voices and provide it in ways that people can relate to and connect with," said Tina Hoff, Senior Vice President at KFF and Executive Director of the organization's Social Impact Media Program.

Google also announced it would expand its health equity research program, first announced last spring as the Fitbit Health Equity Initiative. The expanded program, now called the Google Health Equity Research Initiative, will offer selected researchers at academic institutions and nonprofits in the U.S. access to direct funding, Google Cloud credits, Fitbit devices, and analytics platform Fitabase's services.

Apple introduced Apple Watch Series 8 and the new Apple Watch SE, which bring groundbreaking technology and performance, and important safety innovations to the two best-selling smartwatches. Apple Watch Series 8 features the beloved design of the Apple Watch, including a large, always-on retina display and a strong crack-resistant front crystal. With all-day 18-hour battery life, Apple Watch Series 8 builds on best-in-class health and safety features like the ECG app and fall detection by introducing temperature-sensing capabilities, retrospective ovulation estimates, crash detection, and international roaming. The new Apple Watch SE delivers the core Apple Watch experience, including Activity tracking, high and low heart rate notifications, and emergency SOS, as well as the new crash detection feature and a completely redesigned back case that perfectly matches the three classic case finishes, all at a more affordable price of $249 (US). Both models are powered by watchOS 9, introducing new and more customizable watch faces like Lunar and Metropolitan, an enhanced workout app, sleep stages, a first-of-its-kind AFib history feature, and an all-new medications app.

“We hear from customers how Apple Watch helps them stay connected with loved ones, be more active, and live healthier lives,” said Jeff Williams, Apple’s Chief Operating Officer. “Apple Watch Series 8 reinforces our commitment in these areas with the addition of pioneering technology, while Apple Watch SE brings advanced core features at a new starting price. Powered by watchOS 9, the best smartwatches deliver more capabilities than ever before.”

Wrist Temperature Sensing for Women’s Health

The menstrual cycle is an important marker of health, and many physicians consider it a vital sign. Apple Watch Series 8 features innovative new temperature-sensing capabilities that give women further insights into their health, designed with the same privacy protections as with all other health data. Utilizing the new temperature-sensing capabilities in Apple Watch Series 8, users can receive retrospective ovulation estimates. Knowing when ovulation has occurred can be helpful for family planning, and Apple Watch Series 8 makes it easy and convenient by providing these estimates in the Health app. Temperature sensing also enables improved period predictions.

Additionally, with iOS 16 and watchOS 9, all cycle tracking users can now receive a notification if their logged cycle history shows a possible deviation, such as irregular, infrequent, or prolonged periods, and persistent spotting, which can be symptoms of underlying health conditions.

Apple Watch Series 8 takes a unique approach to temperature sensing with a two-sensor design — one sensor on the back of the watch, nearest the skin, and another just under the display —reducing bias from the outside environment, reports Apple. Nighttime wrist temperature can be a good indicator of overall body temperature. The sensors in Apple Watch Series 8 sample the wrist temperature during sleep every five seconds and measure changes as small as 0.1° C. In the Health app, users can see nightly shifts in baseline temperature, which can be caused by exercise, jet lag, or even illness.

Crash Detection

To enable crash detection, Apple developed an advanced sensor-fusion algorithm that leverages a new, more powerful gyroscope and accelerometer on Apple Watch, which now has the highest dynamic range accelerometer in any smartwatch.

Read more: Apple Could Soon Launch AR/VR Headset with 8K Display

When Apple Watch detects a severe car crash, the device will check in with the user and dial emergency services if they are unresponsive after a 10-second countdown. Emergency responders will receive the user’s device location, which is also shared with the user’s emergency contacts. When combined, crash detection on Apple Watch and iPhone work seamlessly to get users help efficiently.

Low-Power Mode

To keep users connected for even longer, a new low-power mode can extend battery life to reach up to 36 hours for Apple Watch Series 8 with iPhone present. This new mode temporarily disables or limits select sensors and features, including the always-on retina display, workout autostarts, heart health notifications, and more.

watchOS9

The latest software brings new features and enhanced experiences to the world’s leading wearable operating system:

• With international roaming coming later this fall, users can stay connected to a cellular network while traveling abroad. Plans can be extended to Apple Watch from iPhone for little or no additional fee and will be available with over 30 carriers worldwide.
• Users who are diagnosed with AFib can turn on the FDA-cleared AFib History feature and access important information, including an estimate of how frequently their heart rhythm shows signs of AFib, providing deeper insights into their condition. Users will receive notifications with an estimate from the previous week and also have access to a detailed history in the Health app on iPhone, including lifestyle factors that may influence AFib, like sleep, alcohol consumption, and exercise.
• The completely redesigned Compass app in watchOS 9 surfaces more in-depth information and three distinct views. The app displays a new hybrid view that simultaneously shows both an analog compass dial and a digital view. Turning the Digital Crown reveals an additional view that includes latitude, longitude, elevation, and incline, as well as an orienteering view showing Compass Waypoints and Backtrack.
• The Workout app in watchOS 9 includes new in-session views, such as segments, splits, and elevation that offer more precise workout data. Users can also improve their training with advanced workout experiences, including heart rate zones, custom workouts, pacer, and, coming later this year, race route.
• Sleep tracking in watchOS 9 provides even more insights with the introduction of sleep stages.
• The new medications experience on Apple Watch and iPhone helps users manage and track their medications, vitamins, and supplements, allowing them to create a medications list, set up schedules and reminders, and view information on their medications in the Health app.

AppleWatch SE

The new Apple Watch SE delivers advanced features at a new low price and is a great way for users to start their Apple Watch journey, use it with Family Setup, or gift to their loved ones. Powerful upgrades include the S8 SiP advanced dual-core processor, the same processor that is in Apple Watch Series 8 and Apple Watch Ultra, making it 20 percent faster than the previous generation, along with crash detection and international roaming.

Apple Watch SE maintains the same case design but features a redesigned matching back case made of a nylon composite material, making it lighter than ever. With watchOS 9, Apple Watch SE users can enjoy the benefits of the new Compass app in addition to the enhanced fitness and wellness features. Apple Watch SE is available in 40mm and 44mm aluminum cases, in midnight, starlight, and silver finishes, and is compatible with all bands.

AppleWatch and the Environment

Apple Watch Series 8 and Apple Watch SE are designed to minimize their impact on the environment. Both models are made with 100 percent recycled aluminum in the case, 100 percent recycled tungsten in the Taptic Engine, and 100 percent recycled rare earth elements in all magnets. In a first for Apple Watch, both models feature 100 percent recycled gold — in the plating of multiple printed circuit boards on the Apple Watch Series 8, and in the plating of the SiP on the new Apple Watch SE. Both models are free of mercury, BFRs, PVC, and beryllium. No Apple Watch packaging uses outer plastic wrap, and 94 percent or more of the packaging is fiber-based, bringing Apple closer to its goal of completely removing plastic from its packaging by 2025.

Privacy

Privacy is fundamental in the design and development of all of Apple’s features. When a user’s iPhone is locked with a passcode, Touch ID, or Face ID, all of their health and fitness data in the Health app — other than Medical ID — is encrypted. Any health data backed up to iCloud is encrypted both in transit and on Apple servers. When using iOS and watchOS with the default two-factor authentication and a passcode, Health app data synced to iCloud is encrypted end-to-end, meaning that Apple does not have the key to decrypt the data and therefore cannot read it.

Pricing and Availability

Customers in Australia, Canada, France, Germany, India, Japan, the UAE, the UK, the US, and more than 40 other countries and regions can order Apple Watch Series 8 and Apple Watch SE today, with availability in stores.

Apple Watch Series 8 starts at $399 (US) and Apple Watch SE starts at $249 (US).

Evernorth, the health services business of Cigna Corporation, has expanded its Digital Health Formulary to include five new app-based programs to help people better manage their sleep issues, anxiety, alcohol and opioid use disorders, and inflammatory conditions. In a crowded digital health marketplace, Evernorth's Digital Health Formulary is a clinically based platform of verified, credible health apps designed to help people achieve their health goals.  

Solutions on the Evernorth Digital Health Formulary have been reviewed by physicians, pharmacists, and user experience experts. Each solution must meet standards for clinical effectiveness, compliance security and privacy requirements, value, and usability to be included, according to a press release.

"Evernorth continues to expand our Digital Health Formulary to address unmet health care needs of patients with chronic and complex medical conditions," said Dr. Glen Stettin, Chief Innovation Officer, Evernorth. "The latest additions give patients access to new and affordable options to improve and maintain their health while making it easier and cost-effective for our clients to include these solutions in their benefit plans. The Digital Health Formulary is one of the ways we can connect employers, insurers, and patients with innovative, affordable, and evidence-based care that meet their broader healthcare needs."

Read more: SyncThink Secures CE Mark for Digital Health Platform

The five digital solutions added to the Digital Health Formulary are:

• Big Health's Sleepio for insomnia
• Big Health's Daylight for anxiety
• Quit Genius for alcohol use disorder
• Quit Genius for opioid use disorder, rounding out a suite of addiction support solutions from Quit Genius
• HealthBeacon's Injectable Care Management System for inflammatory conditions

Evernorth has also launched a series of pilot programs, with a variety of scopes and scales, through the Digital Health Formulary to further evaluate the clinical impact and user experience of solutions that address additional categories of care. The four pilot programs are:

• Jasper for oncology
• Zerigo for psoriasis and eczema
• Hinge Health for women's pelvic health, which will enhance Hinge Health's Digital Musculoskeletal Clinic that was added as a preferred solution in 2021
• Lid Sync™ for medication treatment adherence

Benefit plans covering more than 20 million U.S. members offer solutions from the Digital Health Formulary to their members, and it delivers average administrative savings of more than $120,000 per solution. Plan sponsors can choose to offer individual digital solutions or incorporate them into one of Evernorth's connected care programs, which safely integrates biometric data from the digital health solutions with pharmacy, medical, and lab data while protecting patient privacy. With this comprehensive view, plan sponsors can identify gaps in care and health opportunities more quickly than when using a standalone solution — ultimately leading to better health outcomes for patients, improved insights for providers, and greater value for health plans.

About Evernorth

Evernorth creates and connects premier health services offerings, including benefits management, pharmacy, care solutions, insights, and intelligence. With an open approach to partnering across the healthcare landscape, they deliver innovative and flexible solutions for health plans, employers, and government programs. Evernorth capabilities are powered by their family of companies, including Express Scripts, Express Scripts® Pharmacy, Accredo, eviCore, and MDLIVE, along with holistic Evernorth platforms and solutions that elevate health and drive progress for people and businesses. All Evernorth solutions are serviced and provided by or through operating affiliates of Evernorth Health, a wholly-owned subsidiary of Cigna Corporation, or third-party partners.

The "Global Electronic Adhesives Market by Form (liquid, paste, solid), Resin (epoxy, silicone, acrylic), End-Use Industry (communications, computers, consumer electronics, industrial, medical), Product Type and Region - Forecast to 2027 report has been added to ResearchAndMarkets.com's offering.

The electronic adhesives market is projected to grow from USD 4.5 billion in 2022 to USD 6.1 billion by 2027, at a CAGR of 6.1% between 2022 and 2027.

The global electronic adhesives market is driven by the rising demand for advanced and sophisticated electronic devices. The use of electronic devices is increasing in developed as well as developing regions, such as North America and the Asia Pacific.

Read more: Sustainable Solution to Replace Etching Processes

Epoxy is estimated to be the largest resin type segment of the electronic adhesives market. Epoxy resin in electronic adhesives held the largest market share in 2021 in terms of value. The most frequently used resin type for electronic applications is epoxy, either two-part or single-part heat cure products. Occasionally snap-cure epoxies, which cure at a lower temperature than regular single-part epoxies, are used, says a press release.

These adhesives can be used, among others, for bonding components, potting, and encapsulation. Potting compounds are intended to provide a high level of the guard to PCBs and electronic devices by surrounding them in a thick, durable polymer. Epoxy is used when extreme operating conditions require optimum protection.

The Asia Pacific is forecasted to be the fastest-growing electronic adhesives market during the forecast period. It is the largest market for electronic adhesives, and this dominance is expected to continue during the forecast period. High economic growth rate, growing manufacturing industries, cheap labor, increasing electronic adhesives patents, and global shift of consumption and production capacity from the developed markets to the emerging markets in the region are the factors leading to the growth of the electronic adhesives market in the Asia Pacific.

The region's market is driven by high economic growth and heavy automotive, industrial, and medical investments. Its growing middle-class population plays an important role in driving various industries, which has led to industrialization in the region.

Tasso, the leading provider of convenient, clinical-grade blood collection solutions, announced that the U.S. Food and Drug Administration (FDA) has cleared its Tasso+™ lancet as a Class II medical device. The clearance allows the company to market and sell the device to more pharmaceutical companies, healthcare organizations, as well as academic institutions across the country, expanding access to a simple and virtually painless blood collection experience.

Read more: Abbott Wins FDA Breakthrough Device Designation

The Tasso+ device is the first single-use, patient-centric blood collection product to receive Class II clearance from the FDA as part of the new reclassification process for lancets, which are intended to puncture the skin to obtain drops of capillary blood samples. This action is part of the FDA’s ongoing effort to ensure the safe and effective use of blood lancets in the home and health care settings. With this clearance, more pharmaceutical companies will be able to accelerate their decentralized clinical trials, especially for pharmacokinetic and biomarker research endpoints. Healthcare systems and physicians will also be able to use the Tasso+ device with compatible collection tubes to make determinations on blood chemistries for their patients and expand care access. Tasso+ device-based solutions with Class II clearance will be widely available to customers across the USA in Q4 2022, reports BusinessWire.

“With continued industry interest in decentralized clinical trials and diverse testing applications, demand for our high-quality, virtually painless, convenient blood collection solutions is at an all-time high,” said Ben Casavant, Ph.D., CEO and co-founder of Tasso. “This FDA Class II medical device clearance will help improve patient care by relieving traditional phlebotomy-related bottlenecks and enabling more individuals to get the tests they need at the time they are needed. We are excited to unlock a new wave of large commercial opportunities for the company and to lead the industry into the future of remote testing.”

About Tasso

Tasso is an emerging healthcare technology company that is transforming the traditional blood collection paradigm with a patient-centric approach. The company’s devices enable simple, convenient, and virtually painless blood collection for users. Tasso technology has the power to bring healthcare anywhere, any time. Headquartered in Seattle, Washington, Tasso is privately held and funded by federal grants, venture investments, and co-development agreements with industry leaders.

Alphabet's life science offshoot Verily announced it had raised $1 billion in an investment round led by its parent company alongside a shakeup of its executive team.

The new capital will be used to support a variety of the company’s core initiatives focused on real-world evidence generation, healthcare data platforms, research and care, and the underlying technology that drives this work, which all share the goal of making healthcare better and more tailored to individuals. The company will also consider further investment in strategic partnerships, global business development, and potential acquisitions.

Read more: Verily and iRhythm Deliver AFib Detecting Zio Watch

As the company enters its next phase of growth, company founder Andy Conrad will become Executive Chairman of the Verily Board and current president Stephen Gillett will be promoted to Chief Executive Officer, with both changes effective January 2023. These new roles are the result of thoughtful succession planning led by Conrad and the board and in recognition of the skills and experience required to lead Verily as it becomes a more operationally and commercially focused company executing its precision health strategy, Verily states in a press release.

Gillett joined Verily from Google in 2020 as an operational advisor to the company and to lead Verily’s effort to establish a Cybersecurity Center of Excellence. In November of that year, he was named Chief Operating Officer. Before joining Verily, Gillett was co-founder and CEO of Chronicle, an Alphabet cybersecurity company that is now part of Google Cloud. He continues to be an active advisor to GV and X. Prior to Alphabet, Gillett held a number of executive roles at companies in a variety of industry sectors including Best Buy, Starbucks, and Symantec.

Separately, Deepak Ahuja, CFO, has decided to leave Verily for another opportunity. He will remain an advisor to Verily but depart his current role at the end of September. Verily will begin a search for his replacement immediately.

About Verily

Verily is a subsidiary of Alphabet that is using a data-driven, people-first approach to change the way people manage their health and the way healthcare is delivered. Launched from X in 2015, Verily’s purpose is to bring the promise of precision health to everyone, every day. Verily is focused on generating and activating data from a wide variety of sources, including clinical, social, behavioral and the real world, to arrive at the best solutions for a person based on a comprehensive view of the evidence. Verily uses its recognized expertise and capabilities in technology, data science, and healthcare to enable the entire healthcare ecosystem to drive better health outcomes.

The next generation of robotic technology will produce soft machines and robots that are safe and comfortable for direct physical interaction with humans and for use in fragile environments. Unlike rigid electronics, soft and stretchable electronics can be used to create wearable technologies and implantable electronics where safe physical contact with biological tissue and other delicate materials is essential.

Soft robots that safely handle delicate fruits and vegetables can improve food safety by preventing cross-contamination. Robots made from soft materials can brave the unexplored depths of the sea to collect delicate marine specimens. And the many biomedical applications for soft robots include wearable and assistive devices, prostheses, soft tools for surgery, drug delivery devices, and artificial organ function, reports Carnegie Mellon University.

But creating these nearly imperceptible components that can seamlessly integrate with human life is only the first step. Mainstream adoption and commercialization of soft and stretchable electronics will require the development of new manufacturing techniques that are scalable and reproducible. Although a variety of methods have already demonstrated the ability to fabricate liquid-metal-based devices on a smaller scale in labs, these methods have not yet resulted in the critical combination of desired features required to produce liquid-metal-based soft and stretchable electronics at a commercially viable scale.

A team of researchers from Carnegie Mellon University’s College of Engineering seeks to change this with a novel method they have developed for mass manufacturing of liquid-metal-based soft and stretchable electronic devices. Their work was recently published in Advanced Materials Technologies.

Kadri Bugra Ozutemiz, who recently earned his Ph.D. in mechanical engineering, has developed a new approach that achieves scalability, precision, and microelectronic compatibility by combining the use of liquid metal with photolithography and wafer-based dip coating. Ozutemiz, who worked with Carmel Majidi and Burak Ozdoganlar, both professors of mechanical engineering, explains that liquid metals have become popular in recent years as a conductor for stretchable circuits to create sensors and antennas as well as soft and stretchable wiring for various electronics and robotics applications.

The gallium-based alloy, eutectic gallium–indium (EGaIn), is liquid at room temperature, can freely flow inside channels, has high electrical conductivity, and can be deformed as long as it is encapsulated in another medium.

Read more: Soft Semiconductors that Stretch Like Human Skin Can Detect Ultra-low Light Levels

“We had to better understand the inherent properties of gallium-based liquid alloys to overcome challenges that make them unsuitable for mass manufacturing,” said Ozutemiz. The most significant challenge was that a thin gallium-oxide “skin” rapidly forms when the liquid metal is exposed to air, which makes it difficult to achieve a uniform and continuous shape or geometry. The liquid metal sticks everywhere, flowing into a wide variety of changeable shapes.

“Our team devised a novel approach that combines selective metal-alloy wetting that deposits the liquid metal into the desired circuit layout with a dip coating process that dissolves the oxide skin that results when EGaln is exposed to the air,” explained Ozutemiz.

Thin metal traces, made of affordable and readily available copper, are first lithographically patterned onto an elastomer surface as a wetting layer. The traces serve as templates for selectively depositing the EGaln onto the silicone rubber surface. In order to dissolve the oxide skin while maintaining the selective deposition of the liquid metal, the researchers devised a novel approach that combined the selective metal alloy wetting with a dip coating process.

Dip-coating, which has been used in the microelectronics industry, but not with liquid metals, facilitates the deposition of EGaIn selectively onto the circuit layout defined by lithographically patterned copper traces on elastomer-coated wafers in a scalable manner.

An automated, high-precision motion system and a two-layer dipping bath are used to deposit the EGaIn onto the patterned copper wetting layer. The bath includes a thin layer of aqueous sodium hydroxide (NaOH) solution at the top surface, followed by the EGaIn. The NaOH solution facilitates the removal of oxide skin and of any oxidation on the surface of the copper traces when the patterned wafer is dipped into the bath. The wafer is then immersed in the bath, and after a short dwell time, is withdrawn at a prescribed speed that controls the amount of liquid deposited on the substrate.

The researchers used a custom-built simple machine to dip the wafers into the bath. By controlling the withdrawal speed, they successfully produced repeatable liquid metal geometries.

In future testing, they will work to control parameters such as withdrawal speed and the amount of time the wafer remains in the bath in order to better understand what effect each variable has on the resulting geometry. But for now, they have established a viable process for the mass production of liquid metal circuits that can be used in a wide variety of soft robotic and electronics applications.

“For us, what was most important was that we achieve repeatable results with a standard process that is already used by chip manufacturers,” said Ozutemiz, who explained that by introducing new material into a well-established process, manufacturers will be able to scale production that will allow for more widespread adoption of these innovative soft robots and electronic devices.

Lenovo announced the new Lenovo Glasses T1 wearable private display for on-the-go content consumption. Compatible with many of today’s modern smartphones, tablets, and laptops with full-function USB-C, the Lenovo Glasses T1 offers superb image quality, high-efficiency optics for extended battery life, and is lightweight so users can explore and enjoy content well beyond the limited screen size of mobile devices.

With mobile devices growing in computing power, mobile gamers, road warriors, and just about everyone else will benefit from the power of carrying a personal monitor in their pocket. The trend is clear, mobile device users want to be able to play more games and stream more videos. The global market for mobile gaming is projected to reach US$153 billion by 2027, growing at an annual growth rate of 11.5%, while the market for video streaming is forecasted to reach US$972 billion by 2030, growing 18.1% on average annually.

These glasses are not just about fun and games. As hybrid work has become the new norm, professionals are looking to get more done on their mobile devices, but working on private business-critical documents on a PC in public spaces creates risk. Using the Lenovo Glasses T1, workers have a private workspace to prevent shoulder surfing, reports Lenovo.

The Lenovo Glasses T1 is ready to meet the demands of many different users. In addition to most full-function USB-C-equipped Windows, Android, and MacOS devices, the glasses can also connect with Lightning Connector-equipped iOS devices via an optional adapter. To maximize comfort for extended use, the Lenovo Glasses T1 is equipped with swappable nose clips, adjustable temple arms and supports custom prescription lenses via an in-box attachable frame.

Superb image quality is achieved with leading-edge micro-OLED display technology, delivering incredible color richness and a super-high contrast ratio of 10,000:1. With high optical efficiency and low overall power consumption, the Lenovo Glasses T1 can stream videos or play games from tethered mobile devices for up to hours without worrying about draining the batteries of the connected devices.

Read more: Google Shows Off AR Glasses With Translation In Real Time

“Every day, people all over the world are increasingly shifting to mobile devices for entertainment and productivity,” said Eric Yu, Senior Vice President of Commercial Product Center and SMB Segment, Intelligent Devices Group, Lenovo. “Screen real estate can be a big bottleneck in the user experience. With a solution like the Lenovo Glasses T1, users have a portable and private big screen experience and can get more value from their phones and laptops.”

The Lenovo portfolio of solutions for consumers and workers offers better experiences through complementary technologies. Users of Motorola smartphones can leverage Ready For to amplify their gaming and entertainment experience with the Lenovo Glasses T1. Ready For unleashes the full power of smartphones making it easier to connect to portable monitors, keyboards, and other devices for an immersive, one-of-a-kind experience.

Pricing and Availability

The Lenovo Glasses T1 (known as Lenovo Yoga Glasses in China) will go on sale in China in late 2022 and be available in other select markets in 2023. The price for the wearable display solution will be announced upon availability.

Key Specs:

Lenovo Glasses T1

Display: Micro OLED

Resolution: 1920 X 1080 per eye

Frame rate: 60Hz

Audio: High-fidelity built-in speakers

Certifications: TUV Low Blue Light, TUV Flicker Reduced

Device Compatibility: Android (Requires Full-functional USB-C only); Windows; iOS with Lightning connector (Requires HDMI to Glasses Adapter, Apple Lightning Digital AV Adapter).

About Lenovo

Lenovo is a US$70 billion revenue global technology powerhouse, ranked #171 in the Fortune Global 500, employing 75,000 people around the world, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver smarter technology for all, Lenovo has built on its success as the world’s leading PC player by expanding into new growth areas of infrastructure, mobile, solutions, and services. This transformation together with Lenovo’s world-changing innovation is building a more inclusive, trustworthy, and sustainable digital society for everyone, everywhere.

Scientists have created a ‘digital mask that will allow facial images to be stored in medical records while preventing potentially sensitive personal biometric information from being extracted and shared. In a research published in Nature Medicine in September, a team led by scientists from Cambridge and China used three-dimensional (3D) reconstruction and deep learning algorithms to erase identifiable features from facial images while retaining disease-relevant features needed for diagnosis.

Facial images can be useful for identifying signs of disease. For example, features such as deep forehead wrinkles and wrinkles around the eyes are significantly associated with coronary heart disease, while abnormal changes in eye movement can indicate poor visual function and visual cognitive developmental problems. However, facial images also inevitably record other biometric information about the patient, including their race, sex, age, and mood.

With the increasing digitalization of medical records comes the risk of data breaches. While most patient data can be anonymized, facial data is more difficult to anonymize while retaining essential information. Common methods, including blurring and cropping identifiable areas, may lose important disease-relevant information, yet even so cannot fully evade face recognition systems, reports the University of Cambridge. Due to privacy concerns, people often hesitate to share their medical data for public medical research or electronic health records, hindering the development of digital medical care.

“During the COVID-19 pandemic, we had to turn to consultations over the phone or by video link rather than in person. Remote healthcare for eye diseases requires patients to share a large amount of digital facial information. Patients want to know that their potentially sensitive information is secure and that their privacy is protected,” said Professor Haotian Lin, Sun Yat-sen University, Guangzhou, China.

Professor Lin and colleagues developed a digital mask, which inputs an original video of a patient’s face and outputs a video based on the use of a deep learning algorithm and 3D reconstruction while discarding as much of the patient’s personal biometric information as possible – and from which it was not possible to identify the individual.

Deep learning extracts features from different facial parts, while 3D reconstruction automatically digitizes the shapes and movement of 3D faces, eyelids, and eyeballs based on the extracted facial features. Converting the digital mask videos back to the original videos is extremely difficult because most of the necessary information is no longer retained in the mask. Next, the researchers tested how useful the masks were in clinical practice and found that diagnosis using the digital masks was consistent with that carried out using the original videos. This suggests that the reconstruction was precise enough for use in clinical practice.

Read more: This Wearable Face Mask Diagnoses COVID-19 And Alerts The Wearer

Compared to the traditional method used to "de-identify" patients – cropping the image – the risk of being identified was significantly lower in the digitally-masked patients. The researchers tested this by showing 12 ophthalmologists digitally masked or cropped images and asking them to identify the original from five other images. They correctly identified the original from the digitally-masked image in just over a quarter(27%) of cases; for the cropped figure, they were able to do so in the overwhelming majority of cases (91%). This is likely to be an overestimation, however: in real situations, one would likely have to identify the original image from a much larger set.

The team surveyed randomly selected patients attending clinics to test their attitudes towards digital masks. Over 80% of patients believed the digital mask would alleviate their privacy concerns and they expressed an increased willingness to share their personal information if such a measure was implemented. Finally, the team confirmed that the digital masks can also evade artificial intelligence-powered facial recognition algorithms.

Professor Patrick Yu-Wai-Man from the University of Cambridge said: “Digital masking offers a pragmatic approach to safeguarding patient privacy while still allowing the information to be useful to clinicians. At the moment, the only options available are crude, but our digital mask is a much more sophisticated tool for anonymizing facial images. "This could make telemedicine – phone and video consultations – much more feasible, making healthcare delivery more efficient. If telemedicine is to be widely adopted, then we need to overcome the barriers and concerns related to privacy protection. Our digital mask is an important step in this direction.”

The research was a collaboration led by scientists from the Zhongshan Ophthalmic Center, Sun Yat-sen University in Guangzhou; Tsinghua University in Beijing, China; and the University of Cambridge.